| Dr Ricardo Jose Arroyo, MD | |
|
1 Ave Casa Linda Suite 101, Carr 177 Los Filtros, Bayamon, PR 00959-8998 | |
| (787) 789-1919 | |
| (787) 999-3069 |
| Full Name | Dr Ricardo Jose Arroyo |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 44 Years |
| Location | 1 Ave Casa Linda Suite 101, Bayamon, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750491056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 8058 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinica Las Americas Guaynabo, Inc | 3476504077 | 38 |
News Archive
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Researchers at the UPM suggest that the interaction between two proteins can be the responsible for the allergic asthma episodes after eating an infected fruit.
Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.
Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.
A team of researchers from City University of Hong Kong and Karolinska Institutet has recently developed a new protein that can help increase the targeting accuracy in the genome editing process. It is believed that it would be useful for future gene therapies in human, which require high precision.
› Verified 9 days ago
| Entity Name | Clinica Las Americas Guaynabo, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326096058 PECOS PAC ID: 3476504077 Enrollment ID: O20050201000414 |
News Archive
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Researchers at the UPM suggest that the interaction between two proteins can be the responsible for the allergic asthma episodes after eating an infected fruit.
Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.
Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.
A team of researchers from City University of Hong Kong and Karolinska Institutet has recently developed a new protein that can help increase the targeting accuracy in the genome editing process. It is believed that it would be useful for future gene therapies in human, which require high precision.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ricardo Jose Arroyo, MD Po Box 7891, Pmb 509, Guaynabo, PR 00970-7891 Ph: (787) 789-1919 | Dr Ricardo Jose Arroyo, MD 1 Ave Casa Linda Suite 101, Carr 177 Los Filtros, Bayamon, PR 00959-8998 Ph: (787) 789-1919 |
News Archive
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Researchers at the UPM suggest that the interaction between two proteins can be the responsible for the allergic asthma episodes after eating an infected fruit.
Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.
Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.
A team of researchers from City University of Hong Kong and Karolinska Institutet has recently developed a new protein that can help increase the targeting accuracy in the genome editing process. It is believed that it would be useful for future gene therapies in human, which require high precision.
› Verified 9 days ago
Jannette Marie Figueroa-velez, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 100 Paseo San Pablo, Edif Dr Arturo Cadilla Vinas Suite 104, Bayamon, PR 00960 Phone: 787-269-2442 | |
Dr. Ana I Rivera De La Vega, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 100 Paseo San Pablo, Edif. Dr. Arturo Cadilla, Suite 201, Bayamon, PR 00961 Phone: 787-778-8774 Fax: 787-269-6190 | |
Boris M Guzman-hernandez, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: Mq10 Plaza 37, Monte Claro, Bayamon, PR 00961 Phone: 787-245-8870 Fax: 787-858-0434 | |
Jose M Rodriguez Castro, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Edif Metromedical, A- 608, Bayamon, PR 00959 Phone: 787-395-7125 Fax: 787-395-7126 | |
Dalvert H Polanco, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 100 Ave Laurel, Bayamon, PR 00956 Phone: 787-787-5151 | |
Dr. Isabel E Cestero, M. D. Gastroenterology Medicare: Medicare Enrolled Practice Location: Route #2 Km 11.7 Bayamon Medical Plaza, Suite 409-b, Bayamon, PR 00959 Phone: 787-786-0473 Fax: 787-786-9718 | |
Joham Senior Marino, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Piso 1 Suite 104a, Bayamon Medical Plaza, Bayamon, PR 00960 Phone: 787-798-9522 Fax: 787-798-9500 |